Abernathy MM - Search Results

1

Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.

Reynolds VL, Butler P, Abernathy MM, Aschenbrenner L, Best DD, Blank J, Crosby M, Custer L, Escobar PA, Kolaja K, Moggs J, Shuey D, Snyder C, Van Vleet T, Zhou J, Hart TK. Reynolds VL, et al. Among authors: abernathy mm. Regul Toxicol Pharmacol. 2020 Nov;117:104746. doi: 10.1016/j.yrtph.2020.104746. Epub 2020 Sep 8. Regul Toxicol Pharmacol. 2020. PMID: 32911461

2

An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation.

Authier S, Abernathy MM, Correll K, Chui RW, Dalton J, Foley CM, Friedrichs GS, Koerner JE, Kallman MJ, Pannirselvam M, Redfern WS, Urmaliya V, Valentin JP, Wisialowski T, Zabka TS, Pugsley MK. Authier S, et al. Among authors: abernathy mm. Int J Toxicol. 2020 Jul/Aug;39(4):274-293. doi: 10.1177/1091581820921338. Epub 2020 May 14. Int J Toxicol. 2020. PMID: 32406289

3

Comparison of validity of standard nonclinical group size selection versus standard clinical group sizes for nonhuman primate QTc prolongation evaluation.

Holdsworth D, Best DD, Haist K, O'Donohue K, Phillips A, Abernathy MM, Roche B, Leishman DJ. Holdsworth D, et al. Among authors: abernathy mm. J Pharmacol Toxicol Methods. 2023 Mar-Apr;120:107253. doi: 10.1016/j.vascn.2023.107253. Epub 2023 Feb 16. J Pharmacol Toxicol Methods. 2023. PMID: 36806737

4

A comparison of the performance of contemporary, historical, and cross-lab controls in QTc assessment in conscious nonhuman primates.

Abernathy MM, Best DD, Leishman DJ. Abernathy MM, et al. J Pharmacol Toxicol Methods. 2024 May-Jun;127:107510. doi: 10.1016/j.vascn.2024.107510. Epub 2024 May 4. J Pharmacol Toxicol Methods. 2024. PMID: 38705245

5

Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation.

Abernathy MM, Best DD, Leishman DJ. Abernathy MM, et al. Clin Pharmacol Ther. 2024 Nov;116(5):1164-1167. doi: 10.1002/cpt.3389. Epub 2024 Jul 17. Clin Pharmacol Ther. 2024. PMID: 39016155 No abstract available.

6

Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation.

Friedrichs GS, Abernathy MM, Ackley D, Clark M, DaSilva JK, Foley CM, Greiter-Wilke A, Henderson KA, Kremer JJ, Morimoto BH, Paglialunga S, Pugsley MK, Regan CP, Rossman EI, Segretti JA, Traebert M, Vargas HM, Wisialowski TA. Friedrichs GS, et al. Among authors: abernathy mm. Regul Toxicol Pharmacol. 2024 Nov;153:105706. doi: 10.1016/j.yrtph.2024.105706. Epub 2024 Sep 16. Regul Toxicol Pharmacol. 2024. PMID: 39293707

7

A "one-step" approach to heart rate correction and statistical analysis applied to conscious dog QTc studies.

Best DD, Abernathy MM, Leishman DJ. Best DD, et al. Among authors: abernathy mm. Clin Transl Sci. 2024 Oct;17(10):e70046. doi: 10.1111/cts.70046. Clin Transl Sci. 2024. PMID: 39404505 Free PMC article.

8

Demonstrating the statistical and pharmacological sensitivity of nonclinical QTc analysis using a dofetilide dose-response in nonhuman primates.

Leishman DJ, Holdsworth DL, Best DD, Abernathy MM, Roche BM. Leishman DJ, et al. Among authors: abernathy mm. J Pharmacol Toxicol Methods. 2024 Dec 15;131:107572. doi: 10.1016/j.vascn.2024.107572. Online ahead of print. J Pharmacol Toxicol Methods. 2024. PMID: 39689735

9

A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium.

Boulay E, Abernathy MM, Chui R, Friedrichs GS, Gendron-Parra N, Greiter-Wilke A, Guillon JM, Koerner JE, Menard A, Steidl-Nichols J, Pierson J, Pugsley MK, Rossman EI, Strauss D, Troncy E, Valentin JP, Wisialowski T, Authier S. Boulay E, et al. Among authors: abernathy mm. Int J Toxicol. 2019 Jan/Feb;38(1):23-32. doi: 10.1177/1091581818813601. Epub 2018 Dec 19. Int J Toxicol. 2019. PMID: 30567462

10

The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities.

Abernathy MM, Leishman DJ. Abernathy MM, et al. Clin Pharmacol Ther. 2024 Jul;116(1):22-25. doi: 10.1002/cpt.3219. Epub 2024 Feb 21. Clin Pharmacol Ther. 2024. PMID: 38384137

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters